Makes them a good "buy out" ctarget as well..imo
2 European PHASE III trials due out any time now.
NIMOTUZUMAB(many areas of applications) POTENTIAL Best In Class drug
* Could trigger a sub-licensing activity by Oncoscience
*Japanese Phase II results may encourage progression into Phase III, and progression in clarifying the Cuban situation/US approvals suggests potential for US parterning
THEIR STAR DRUG (worth billions..imo)
Nimotuzumab is a humanized monoclonal antibody in development worldwide, targeting multiple tumor types primarily in combination with radiation and chemoradiation. It is importantly differentiated from all other currently marketed EGFR-targeting agents due to its remarkably benign side-effect profile.
Nimotuzumab's anti-tumor activity has led to its approval
for marketing in 23 countries. In more than 9,000 patients reported as having been treated with nimotuzumab worldwide to date, Grade IV incidents of radiation dermatitis and incidents of severe rash have been only rarely observed and reports of the other severe side-effects that are typical of EGFR-targeting molecules have been equally rare. Nimotuzumab is licensed to YM's majority-owned, Canadian subsidiary, CIMYM BioSciences Inc., by CIMAB S.A., and was developed at the Center of Molecular Immunology. The products discovered by YM's recently acquired Australian subsidiary, YM BioSciences Australia, include the JAK 1/2 inhibitor CYT387 and the novel VDA molecule CYT997. Both were discovered internally at Cytopia based on research led by Dr. Andrew Wilks who identified the JAK 1/2 kinase enzymes. Both products are currently in clinical development.
YMI GOT EXCELLENT NEWS REGARDING THEIR PATENT(S)
YM BioSciences Inc. announced two additional patents in the US for AeroLEF, the Company's inhaled-delivery composition of free and liposome-encapsulated fentanyl in development for the treatment of moderate to severe acute pain.
US patent numbers 7,648,981 and 7,648,982 extend the life of YM's AeroLEF patent estate in the US to 2024. The Company also announced that AeroLEF's patent estate has expanded to include other territories with the issuance of European patent number 1,603,533 and several patent allowances in China, India, Mexico and other territories. [/b]US patent number 7,648,981 protects the self-medicating method of pain management in which the pain sufferer inhales a formulation comprising free and liposomal fentanyl in a dose ratio that provides rapid onset and sustained relief from pain without attendant toxicity. Also claimed is a breath-actuated device for delivering the fentanyl formulation. US patent number 7,648,982 similarly covers a pain relief method and device that delivers fentanyl formulations defined according to the particle sizes and unit doses effective to manage pain by the route of pulmonary delivery. European patent number 1,603,533 and other recently allowed patents' coverage is similar in scope to the recently issued US patents.
Looks like a few PHASE III results should be coming. MANY CATALYSTS. MUST DO DD TO SEE POTENTIAL.
Could be huge. Smells more like a multi-bagger...imo
